The Effects of vasodilators in pulmonary hypertension pulmonary vascular or peripheral vascular?

Circulation: Heart Failure

Volumn 2, Issue 2, 2009, Pages 145-150

  Rich, Stuart ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HYDRALAZINE; ILOPROST; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; UNIPROST; VASODILATOR AGENT;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MEGADOSE; ERECTILE DYSFUNCTION; ERGOMETRY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HUMAN; INTERMITTENT CLAUDICATION; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MUSCLE STRENGTH; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; TREATMENT RESPONSE;

BLOOD VESSELS; EXERCISE TOLERANCE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LUNG; MUSCLE, SKELETAL; REFLEX; REGIONAL BLOOD FLOW; RESPIRATION; TIME FACTORS; VASODILATION; VASODILATOR AGENTS; WALKING;

EID: 77953666423     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.805374     Document Type: Review

References (77)

1. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension, I: Clinical and hemodynamic study. Am J Med. 1951; 11:686 -705.
2. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J. 1958; 20:557-567.
3. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111:3105-3111.
4. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126: 35S-62S. (Pubitemid 38932341)
5. Scott AC, Francis DP, Davies LC, Ponikowski P, Coats AJ, Piepoli MF. Contribution of skeletal muscle 'ergoreceptors' in the human leg to respiratory control in chronic heart failure. J Physiol. 2000; 529(Pt 3):863- 870.
6. Hegewald M, Markewitz B, Elliott G. Pulmonary hypertension: clinical manifestations, classification and diagnosis. Int J Clin Pract. 2007; 61:5-14.
7. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation. 2008; 118: 1195-1201.
8. Rich S, Kaufman E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327:76-84.
9. Rich S, D'Alonzo G, Dantzker D, Levy PS. Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. Am J Cardiol. 1985; 55:159 -163.
10. Palevsky H, Schloo B, Pietra G, Weber K, Janicki J, Rubin E, Fishman A. Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989; 80:1207-1221.
11. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Elliott CG, Fishman AP, Goldring RM, Groves BM, Kernis JT, Koerner SK, Levy PS, Pietra GG, Reid LM, Rich S, Vreim CE, Williams GW. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis. 1989; 140:1623-1630.
12. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2008; 118:2372-2379.
13. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351:1425-1436.
14. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest. 2007; 131:1917-1928.
15. Pietra G, Edwards W, Kay J, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Dietre KM, Fishman AP, Goldring RM, Groves BM, Levy PS, Reid LM, Vreim CE, Williams GW. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989; 80:1198 -1206.
16. Cool C, Kennedy D, Voelkel N, Tuder R. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 1997; 28: 434-442.
17. Black SM, Mata-Greenwood E, Dettman RW, Ovadia B, Fitzgerald RK, Reinhartz O, Thelitz S, Steinhorn RH, Gerrets R, Hendricks-Munoz K, Ross GA, Bekker JM, Johengen MJ, Fineman JR. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation. 2003; 108:1646 -1654.
18. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008; 67:808-814.
19. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165:800-804. (Pubitemid 34229650)
20. Galie N, Humbert M, Vachiery J-L, Vizza C, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002; 39:1496 -1502. (Pubitemid 34439066)
21. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353:2148 -2157. (Pubitemid 41653106)
22. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, II: Pathophysiology, clinical importance, and management of right ventricular failure Part II. Circulation. 2008; 117: 1717-1731.
23. Malik AS, Warshafsky S, Lehrman S. Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension. Arch Intern Med. 1997; 157:621- 625.
24. Channick R, Simonneau G, Sitbon O, Robbins I, Frost A, Tapson V, Badesch D, Roux S, Rainisio M, Bodin F, Rubin L. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358: 1119-1123. (Pubitemid 32971843)
25. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 169:441- 447.
26. Barst R, Rubin L, Long W, McGoon M, Rich S, Badesch D, Groves B, Tapson V, Bourge R, Brundage B, Koerner S, Langleben D, Keller C, Murali S, Uretsky B, Clayton L, Jobsis M, Blackburn S, Shortino D, Crow J. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334:296 -301. (Pubitemid 26033085)
27. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grunig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006; 114:1482-1489.
28. Fisher JBJ, Moses JW, Goldberg HL, Niarchos AP, Whitman HH III. Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension. Am J Cardiol. 1984; 54:646-650.
29. Packer M, Medine N, Yushak M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol. 1984; 4:890-896.
30. Rich S, McLaughlin V. Endothelin receptor blockers in cardiovascular disease. Circulation. 2003; 108:2184 -2190.
31. Giaid A, Yanagisawa M, Langleben D, Michel R, Levy R, Shennib H, Kimura S, Masaki T, Duguid W, Stewart D. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328:1732-1739. (Pubitemid 23170122)
32. Kedzierski R, Yanagisawa M. Endothelin System: The double-edged sword in health and disease. Ann Rev Pharmacol Toxicol. 2001; 41: 851-876.
33. Mulder P, Richard V, Derumeaux G, Hogie M, Henry J, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure. Circulation. 1997; 96: 1976-1982.
34. Nguyen Q, Cernacek P, Caleroni A, Stewart D, Picard P, Sirois P, White M, Rouleau J. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation. 1998; 98:2323-2330.
35. Ponicke K, Vogelsang M, Heinroth M, Becker K, Zolk O, Bohm M, Zerkowski HR, Brodde OE. Endothelin receptors in the failing and nonfailing human heart. Circulation. 1998; 97:744 -751.
36. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation. 2002; 105: 2398-2403.
37. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006; 5:689 -702.
38. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007; 50:2136 -2144.
39. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007; 116:238 -248.
40. Kass DA. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3? Circulation. 2007; 116:233-235.
41. Christman B, McPherson C, Newman J, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327:70 -75.
42. Badesch D, Tapson V, McGoon M, Brundage B, Rubin L, Wigley F, Rich S, Barst R, Barrett P, Kral K, Jobsis M, Loyd J, Murali S, Frost A, Girgis R, Bourge R, Ralph D, Elliott G, Hill N, Langleben D, Schilz R, McLaughlin V, Robbins I, Groves B, Shapiro S, Medsger T, Gaine S, Horn E, Decker J, Knobil L. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med. 2000; 132:425- 434.
43. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin L, Nikkho S, Speich R, Hoeper M, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani H, Manes A, Kiely D, Ewwert R, Meyer A, Corris P, Delcrox M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347:322-329. (Pubitemid 34815354)
44. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106: 1477-1482.
45. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40:780 -788.
46. Rich S, McLaughlin V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol. 1999; 34:1184 -1187.
47. Kisch-Wedel HKG, Meisner F, Flondor M, Kuebler WM, Bruhn S, Koehler C, Zwissler B. The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo. Intensive Care Med. 2003; 29:1574 -1583.
48. Montalescot G, Drobinski G, Meurin P, Maclouf J, Sotirov I, Philippe F, Choussat R, Morin E, Thomas D. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol. 1998; 82:749 -755.
49. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001; 142:393- 401.
50. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997; 134:44 -54.
51. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L, Tognoni G. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007; 153:1037-1047.
52. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest. 2006; 130:1198 -1202.
53. Roberts K, Preston I, Hill NS. Pulmonary hypertension trials: current end points are flawed, but what are the alternatives? Chest. 2006; 130: 934-936.
54. Castelain V, Chemla D, Humbert M, Sitbon O, Simonneau G, LeCarpentier YP. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med. 2002; 165: 338-340.
55. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med. 1998; 338:784 -790.
56. Yardumian DA, Rustin M, Belcher G, Snaith ML, Dowd PM, Machin SJ. Successful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue. Brit J Rheum. 1988; 27:220 -226. (Pubitemid 18170569)
57. de la Pena-Lefebvre PG, Exposito MV, Carmona L, Gamir MLG, Gutierrez JB, Diaz-Miguel C, Martinez JO, Mendoza ACZ. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology. 2008; 47:464-466.
58. Berman S, Yoder P, Voigt S, Strootman D, Wade M. Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study. Vasc Med. 2006; 14:142-148.
59. Goldstein I, Padma-Nathan H, Rosen R. C, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998; 338:1397-1404.
60. Sueta CA, Gheorghiade M, Adams KF Jr, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol. 1995; 75: 34A-43A.
61. Meyer zu Vilsendorf A, Jorns A, Nagel E, Kohl J. Preconditioning with the prostacyclin analog epoprostenol and cobra venom factor prevents reperfusion injury and hyperacute rejection in doscordant liver xenotransplantation. Xenotransplantation. 2001; 8:41- 47.
62. Mohler ER, Goldman R, Kimmel SE, Wade M, Sefgal CM. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Vasc Med. 2000; 5:231-237.
63. Clark AL, McDonagh T. The origin of symptoms in chronic heart failure. Heart. 1997; 78:429-430.
64. Ponikowski PP, Chua TP, Francis DP, Capucci A, Coats AJ, Piepoli MF. Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation. 2001; 104:2324 -2330.
65. Meyer FJ, Lossnitzer D, Kristen AV, Schoene AM, Kubler W, Katus HA, Borst MM. Respiratory muscle dysfunction in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005; 25:125-130.
66. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999; 99:1173-1182.
67. Lang CC, Chomsky DB, Butler J, Kapoor S, Wilson JR. Prostaglandin production contributes to exercise-induced vasodilation in heart failure. J Appl Physiol. 1997; 83:1933-1940.
68. Wray DW, Nishiyama SK, Donato AJ, Sander M, Wagner PD, Richardson RS. Endothelin-1-mediated vasoconstriction at rest and during dynamic exercise in healthy humans. Am J Physiol Heart Circ Physiol. 2007; 293:H2550-H2556.
69. Guazzi M, Casali M, Berti F, Rossoni G, Colonna VD, Guazzi MD. Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther. 2008; 83:336 -341.
70. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995; 26:1581-1585.
71. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102: 865-870.
72. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004; 110:1308 -1312.
73. Watanabe T, Takeda T, Omiya S, Hikoso S, Yamaguchi O, Nakano Y, Higuchi Y, Nakai A, Abe Y, Aki-Jin Y, Taniike M, Mizote I, Matsumura Y, Shimizu T, Nishida K, Imai K, Hori M, Shirasawa T, Otsu K. Reduction in hemoglobin-oxygen affinity results in the improvement of exercise capacity in mice with chronic heart failure. J Am Coll Cardiol. 2008; 52:779 -786.
74. Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, Kubler W, Haass M. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation. 2001; 103: 2153-2158.
75. Bauer R, Dehnert C, Schoene P, Filusch A, Bartsch P, Borst MM, Katus HA, Meyer FJ. Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension. Respir Med. 2007; 101:2366-2369.
76. Naeije R. Breathing more with weaker respiratory muscles in pulmonary arterial hypertension. Eur Respir J. 2005; 25:6-8.
77. Pina IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, Fletcher BJ, Fleg JL, Myers JN, Sullivan MJ. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation. 2003; 107: 1210-1225.